
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
Donepezil Hydrochloride (Aricept)
Rivastigmine Tartrate (Exelon)
Memantine Hcl (Namenda)
Galantamine Hydrobromide (Razadyne Solution)




